Results 221 to 230 of about 6,512,999 (388)

SGLT-2 inhibitors in cancer patients with diabetes: when cardioprotection is key. [PDF]

Eur Heart J Cardiovasc Pharmacother
Brambilla M, Larroux B, Bonaventura A.
europepmc   +1 more source

THE BACTERIAL GROWTH INHIBITOR (LACTENIN) OF MILK [PDF]

, 1930
F. S. Jones, Henry S. Simms
openalex   +1 more source

Immune-related adverse events of checkpoint inhibitors

Nature Reviews Disease Primers, 2020
M. Ramos-Casals, J. Brahmer, M. Callahan, A. Flores-Chávez, N. Keegan, M. Khamashta, O. Lambotte, X. Mariette, A. Prat, M. Suarez‐Almazor   +9 more
semanticscholar   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design. [PDF]

Discov Oncol
Chen X, Zhang D, Xue J, Li Z.
europepmc   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Identification of Novel Leishmania donovani Nucleoside Hydrolase Inhibitors from Banisteriopsis laevifolia Using Affinity Selection-Mass Spectrometry

ACS Omega
Pamella C. O. de Oliveira, Pedro R. C. Medeiros, Bruno C. B. Marques, Jorge L. S. Simão, Martin Albino, Vanessa G. P. Severino, Claudio Sangregorio, Luzineide W. Tinoco, Marcela C. de Moraes   +8 more
doaj   +1 more source

Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. [PDF]

Research (Wash D C)
Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, Deng X, Xie J, Tang H.   +8 more
europepmc   +1 more source

The Effects of Certain Metabolic Inhibitors on the Dark Reaction during Photoperiodic Treatment

, 1955
Shidai Nakayama
openalex   +2 more sources

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source